Neon Bloom increases authorized Common Stock and creates Series B Preferred Stock
Neon Bloom, through its subsidiary Bazelet Health Systems, is enhancing the cannabis industry with non-psychoactive products. On January 3, 2022, the company received shareholder consent to amend its Articles of Incorporation, increasing its authorized shares to 750 million and creating 2 million shares of Series B Preferred stock. Bazelet is at the forefront of cannabis genome engineering, utilizing CRISPR technology to develop patented therapeutic plants that comply with federal regulations.
- Increased authorized shares to 750 million allows for potential growth and investment.
- Creation of Series B Preferred stock may attract new investors and provide funding opportunities.
- Bazelet is pioneering non-psychoactive cannabis products, positioning itself as a leader in cannabis science.
- None.
ORLANDO, Fla., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Neon Bloom, Inc. (OTC: NBCO), through its wholly owned subsidiary Bazelet Health Systems, Inc., is a professional healthcare organization leading cannabis science and the development of federally compliant, non-psychoactive cannabis products. On January 3, 2022, upon receiving consent from a majority of its voting shareholders, the Company amended its Articles of Incorporation to (i) increase its authorized shares of Common Stock to 750,000,000; and (ii) create a Series B Preferred stock of which it is authorized to issue up to 2,000,000 shares.
About: Bazelet™ is revolutionizing the field of cannabis genome engineering and sequencing and is deeply involved in the scientific, medical, and regulatory communities regarding the cannabis genus. The company is breeding from varieties that are registered and approved globally, including by the EU and AOSCA, and new plant genetics that utilize CRISPR-Cas9 to further advance our unprecedented cannabis genetics library. Bazelet leads the scientific, medical, consumer and regulatory communities with the world’s first patented, federally legal, non-psychoactive, therapeutic cannabis plants and ingredients.
Disclaimer: This Press Release is for informational purposes, contains forward-looking statements based on current expectations, forecasts, and assumptions with information available to us as of the date hereof and involve risks and uncertainties. This Press Release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Actual results may differ materially from those stated or implied in such forward-looking statements. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "would" or similar words. We assume no obligation to update the information included in this Press Release, whether a result of new information, future events or otherwise.
CONTACT: Robyn Frick
EMAIL: media@bazelethealth.com
WEBSITE: www.bazelethealth.com
FAQ
What recent changes were made to Neon Bloom's authorized shares?
What is the significance of the Series B Preferred stock for NBCO?
How is Bazelet Health Systems contributing to cannabis science?
